TRCT
LUCD icon

Tower Research Capital (TRC)’s Lucid Diagnostics LUCD Stock Holding History

Tower Research Capital (TRC)’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.1K Buy
19,711
+584
+3% +$629 ﹤0.01% 3504
2026
Q1 		$22K Buy
19,127
+9,392
+96% +$12K ﹤0.01% 3416
2025
Q4 		$10.6K Sell
9,735
-706
-7% -$789 ﹤0.01% 3736
2025
Q3 		$10.5K Buy
10,441
+10,416
+41,664% +$11.4K ﹤0.01% 3976
2025
Q2 		$29 Sell
25
-5,168
-100% -$6.67K ﹤0.01% 5207
2025
Q1 		$7.74K Sell
5,193
-1,976
-28% -$2.37K ﹤0.01% 3935
2024
Q4 		$5.87K Buy
7,169
+1,102
+18% +$972 ﹤0.01% 4232
2024
Q3 		$4.95K Sell
6,067
-13,731
-69% -$11.2K ﹤0.01% 4364
2024
Q2 		$16.2K Sell
19,798
-175
-0.9% -$148 ﹤0.01% 3870
2024
Q1 		$16.2K Buy
19,973
+18,958
+1,868% +$24.6K ﹤0.01% 3201
2023
Q4 		$1.43K Sell
1,015
-1,976
-66% -$2.6K ﹤0.01% 5382
2023
Q3 		$3.5K Buy
2,991
+2,964
+10,978% +$4.3K ﹤0.01% 4996
2023
Q2 		$38 Sell
27
-3,066
-99% -$4.62K ﹤0.01% 5887
2023
Q1 		$4K Buy
3,093
+532
+21% +$737 ﹤0.01% 5082
2022
Q4 		$3K Sell
2,561
-4,721
-65% -$8.49K ﹤0.01% 5207
2022
Q3 		$11K Buy
+7,282
New +$18.1K ﹤0.01% 4451
2022
Q2 		– Sell
-3,548
Closed -$12K – 6338
2022
Q1 		$12K Buy
3,548
+2,467
+228% +$9.02K ﹤0.01% 4073
2021
Q4 		$6K Buy
+1,081
New +$8.77K ﹤0.01% 5039

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Tower Research Capital (TRC)'s LUCD Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Lucid Diagnostics (LUCD) stake by 3.1% in Q2 2026, buying an estimated $629 and bringing the position to 19,711 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3504.

Tower Research Capital (TRC) first reported a position in LUCD in Q4 2021 and has held it in 18 quarters since. The position peaked at $22K in Q1 2026. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Tower Research Capital (TRC) held 19,711 shares of Lucid Diagnostics worth $21.1K as of Q2 2026.
  • Tower Research Capital (TRC) bought 584 Lucid Diagnostics shares in Q2 2026, an estimated $629.
  • Lucid Diagnostics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3504 holding.
  • Tower Research Capital (TRC) first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s Lucid Diagnostics position peaked at $22K in Q1 2026.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.